Comparing 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer

from TheBrief.Health · host TheBrief.Health

ANDROMEDA trial compares alpha and beta PSMA radioligand therapies with SBRT for recurrent oligometastatic prostate cancer, aiming to improve disease control and quality of life.

Episode metadata supplied by the publisher feed · Published Feb 2, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Comparing 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer

0:00 2:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 2 minutes long.

When was this TheBrief.Health episode published?

This episode was published on February 2, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!